Form 4: Cue Biopharma Executive Granted Stock Options

Daniel G. Baker, Chief Development Officer of Cue Biopharma, Inc., was granted stock options to purchase 100,000 shares of common stock.

Summary

• Daniel G. Baker, the Chief Development Officer of Cue Biopharma, Inc., was granted stock options on March 21, 2025.
• The options allow him to purchase 100,000 shares of Cue Biopharma's common stock at an exercise price of $0.99 per share.
• The stock options vest in eight equal semi-annual installments, starting on September 21, 2025.
• The options expire on March 20, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and aligns their interests with the company's success.

Positives

• The granting of stock options to a key executive like the Chief Development Officer can be seen as an incentive to align their interests with the company's long-term success.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Cue Biopharma.
• Comparable companies such as Moderna, BioNTech, and Novavax also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Development Officer to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Cue Biopharma, Daniel G. Baker, Chief Development Officer, equity compensation, Form 4